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A B S T R A C T
Purpose: Since 2017 treatment-naïve patients infected with genotype 1b of hepatitis C virus and minimal or
moderate fibrosis can be treated with Ombitasvir/Paritaprevir/ritonavir + Dasabuvir (OPrD) for 8 weeks ac-
cording to updated Summary of Product Characteristics. The aim of our study was to assess the comparative
efficacy of 8 and 12-weeks therapy with OPrD in large cohort of patients eligible for 8 weeks regimen treated in
real-world setting.
Materials and methods: We analysed data of 3067 HCV genotype 1b infected patients treated with OPrD between
2015 and 2017. Final analysis included patients with none, minimal or moderate fibrosis (F0–F2).
Results: A total of 771 patients were enrolled in the study, including 197 (26%) treated for 8-weeks and 574
patients fulfilling criteria for 8-weeks but assigned to 12-weeks regimen. Majority of patients had no or minimal
fibrosis (F0–F1). Longer treatment duration was more often administered in patients with moderate fibrosis,
comorbidities, concomitant medications. SVR was achieved in 186 (94%) patients treated for 8 weeks and 558
(97%) for 12 weeks (p = 0.07). After exclusion of lost to follow-up patients, sustained virological response (SVR)
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rate reached 95% and 99%, respectively (p = 0.01). We were not able to identify factors associated with non-
response.
Conclusions: This real-word experience study confirmed similar, high effectiveness of 8 and 12-weeks regimens
of OPrD in genotype 1b HCV infected patients with non-advanced fibrosis. Despite of reduced SVR rate after 8-
weeks regimen, there is no need to extend therapy to 12-weeks in vast majority of such patients and no need to
add ribavirin.
1. Introduction
Chronic hepatitis C virus (HCV) infection is one of leading causes of
liver disease, affecting approximately 71 million people globally. The
most prevalent worldwide is genotype (GT) 1, particularly its subtype
1b, which is predominant in Europe [1]. According to the most recent
analysis GT1b is responsible for more than 80% HCV infections in Po-
land [2]. Therefore at the beginning of the interferon-free era there was
a need of highly effective and tolerable regimen for treatment of pa-
tients infected with this GT. The first available option was ombitasvir/
paritaprevir/ritonavir and dasabuvir (OPrD), which was approved in
the European Union for the treatment of GT1b infected patients for 12
weeks, regardless of liver fibrosis and treatment history [3]. Since 2017,
treatment-naïve patients with chronic GT1b HCV infection with
minimal or moderate fibrosis can be treated with OPrD for 8 weeks.
This update of Product Characteristics was based on the results of a
relatively small Garnet study, which was not supported by any large
real world experience (RWE) study [4]. Shortening of the treatment can
reduce therapy costs, improve patients comfort and adherence to
treatment. So, if it does not cause sustained virological response (SVR)
reduction and can be confirmed in additional study, 8 weeks therapy
should be recommended as an optimal regimen.
The aim of our study was to assess the comparative efficacy of 8 and
12-week regimens of OPrD in patients eligible for 8 weeks therapy in
RWE setting.
2. Patients and methods
2.1. Study design
The analysis was a part of the EpiTer-2 database, a retrospective,
investigator-initiated, manufacturer-independent study evaluating an-
tiviral treatment of HCV infected patients in routine clinical practice,
that included 22 Polish hepatitis treating centres [5,6]. The choice of
the regimen was entirely at the discretion of the treating physicians.
Patients were treated in line with reimbursed therapeutic program of
the Polish National Health Fund and in accordance with the re-
commendations of the Polish Group of Experts for HCV [7]. According
to the protocol of national therapeutic program, patients receiving
OPrD regimen were monitored every 4 weeks for haematology, ALT and
bilirubin level and additionally HCV RNA were measured at the end of
treatment (EOT) and final follow-up visit. HCV RNA detection level
varied across study centres depending on the assay used but was al-
ways< 15 IU/mL as recommended by national guidelines [7]. The
study was supported by the Polish Association of Epidemiologists and
Infectiologists.
2.2. Patients
Among 6228 patients included in the EpiTer-2 database, treated for
chronic HCV infection between 1 July 2015 and 31 December 2017, a
total number of 3067 patients infected with GT1b received OPrD, that
included 771 patients with none, minimal or moderate fibrosis (F0–F2).
In this population 197 patients received 8-weeks regimen, whereas
remaining 574 patients eligible for shorter treatment duration were
assigned to 12-weeks regimen. Decision on the length of treatment was
at the discretion of the treating physician based on the Summary of
Product Characteristics for Viekirax and Exviera (updated in March
2016), that also included ribavirin (RBV) co-administration. We
decided to have 12 weeks regimen with RBV arm in the analysis to
demonstrate possible effect of RBV addition.
2.3. Data analysis
Data concerning baseline variables included demographics, prior
treatment status, stage of liver fibrosis (based mostly on stiffness in
elastography), comorbidities, concomitant medications, HIV and HBV
coinfections, severity of the disease, history of decompensation and
hepatocellular carcinoma, laboratory parameters, treatment regimen,
therapy course, efficacy and safety, were collected retrospectively and
submitted online by questionnaire administered by Tiba sp. z o.o.
The efficacy end point was the SVR defined as undetectable HCV
RNA at least 12 weeks after the end of treatment. The safety of antiviral
therapy was assessed by analysing the most common and most severe
documented adverse events, as well as the rate of treatment dis-
continuation, its modification and deaths.
2.4. Statistical analysis
The results are expressed as mean ± standard deviation (SD) or n
(%). P values of< 0.05 were considered to be statistically significant.
Comparisons between groups were performed with analysis of non-
parametric test. The significance of difference was calculated using the
Fischer's exact test for categorical variables and by the Mann Whitney U
test for continuous variables. Multivariate analysis was performed using
logistic regression with SVR as dependent variable, fibrosis (F0-1 vs
F2), sex and comorbidity as qualitative predictors and age, HCV-RNA
and serum albumins as quantitative predictors. Statistical analyses were
performed using GraphPad Prism 5.1 (GraphPad Software, Inc., La
Jolla, CA, USA).
3. Results
The mean age of the cohort was 47 ± 15 years, and 43% were
males. As shown in Table 1, 49% of the analysed population presented
comorbidities with the most frequent arterial hypertension, and 41%
were treated with co-medications. Longer treatment duration was sta-
tistically significantly more often administered in older patients with
comorbidities and concomitant medications. The majority of patients
had no or minimal fibrosis, and their proportion in the group treated for
8 weeks (84%) was statistically significantly higher compared to pa-
tients treated for 12 weeks (61%). The most common method of liver
fibrosis assessment was transient elastography applied in 56% of pa-
tients (Table 1).
As shown in Fig. 1, overall SVR rate calculated according to the
intent-to-treat (ITT) analysis was achieved in 186/197 (94%) patients
treated for 8 weeks and 558/574 (97%) treated for 12-weeks
(p = 0.07). After exclusion of lost to follow-up patients (modified ITT
(mITT) analysis), SVR rate reached 95% and 99%, respectively
(p = 0.01). Among those treated with OPrD for 12 weeks, 53 patients
(9.2%) received additionally RBV, which did not improved the efficacy
and even caused insignificant reduction of SVR rate compared to pa-
tients treated with OPrD without RBV in both intent-to-treat (ITT) (93%
vs 98%, p = 0.05) and modified ITT (mITT) analysis (96% vs 98%,
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p = 0.29) (Fig. 1). A comparison carried out between the patients
treated for 8 or 12-weeks without RBV revealed SVR rates of 94% vs
98% (p = 0.03) in ITT, and 95% vs 98% (p = 0.02) in mITT analysis,
respectively (Fig. 1). The only factor associated with SVR in multi-
variate analysis was 8 week therapy (p = 0.02), with additional trend
towards higher SVR in female patients (p = 0.06). The likelihood of
SVR was irrespective of age, HCV-RNA, serum albumin, fibrosis ad-
vancement (F0-1 vs F2) as well as the presence of comorbidity.
All 9 non-responders from the 8-weeks arm demonstrated viral load
below 6 million U/l. All except one demonstrated minimal fibrosis (F1)
and 8 were males (Table 2). In the analysed cohort 7 patients (3 males
and 4 females) did not respond to 12-weeks OPrD regimen. Two of
them had liver fibrosis F1 and five F2; among those with moderate fi-
brosis (F2) two received therapy with RBV (Table 3).
We were not able to identify the factors associated with non-re-
sponse to OPrD ± RBV regimen, except for 2 patients in the 8-weeks
group, of whom one did not respond to previous pegIFN and RBV
therapy and the other one stopped the therapy for 1 week (between 4th
and 5th week) because of alcohol abuse.
The majority of patients completed the treatment course as sched-
uled. The therapy was discontinued by 8 patients and modified in 5
others, mostly due to RBV dose reduction in the patients scheduled for
12 weeks regimen with RBV. Approximately 20% of the total study
population experienced at least one adverse event (AE) during the
therapy and it was affected by the presence of RBV in the regimen. The
most common were weakness/fatigue, sleep disorders, headache and
pruritus. Serious AE were reported only in the 12-weeks regimen sub-
population, mainly among patients treated without RBV. There were no
deaths reported (Table 4).
4. Discussion
In the present study, we found a statistically significantly higher
response to the 12-week OPrD therapy than the 8-week therapy among
patients who completed the treatment. The study included patients
treated for 12 weeks before the Summary of Product Characteristics
changes allowed for shortening of their treatment to 8 weeks.
Moreover, as mentioned above the final decision on the regimen, that
included possible RBV co-administration and the length of treatment
was at the physician discretion. Therefore some patients with none or
minimal fibrosis received the 12 weeks regimen.
As mentioned above, shortening of treatment with OPrD was pos-
sible based on the Garnet study, which included 166 patients treated for
8 weeks. It was carried out as a single arm, open label study and pro-
vided SVR rate of 98% [4]. The only RWE study published up to now
with results of 8 weeks OPrD regimen in 200 patients demonstrated
SVR rate of 96% [8]. Based on these two studies we can assume that
SVR rate achieved after 8 weeks was similar to that demonstrated in our
study. However, it must be mentioned, that both of these studies were
single arm, so did not compare 8 vs. 12 weeks regimens in patients
eligible for shortened therapy because of not advanced liver fibrosis.
However such a comparison was carried out in our study.
In the largest RWE study, published by Backus et al. [9], 8 weeks
therapy with ledipasvir/sofosbuvir (LDV/SOF) carried out in 1333 pa-
tients allowed to achieve SVR in 92% patients. Unfortunately, almost all
RWE studies on efficacy of OPrD included patients treated for 12 weeks
or longer and SVR rates ranged from 86% to 99% SVR [9–18].
Our present study included patients infected with HCV GT1b,
without advanced fibrosis, which met criteria for shortening the treat-
ment to 8 weeks according to both Product Characteristics and current
experts recommendations [7,19]. However, the weakness of our study
included differences in patients characteristics since among patients
treated for 8 weeks there were significantly more females, the patients
were younger, demonstrated less advanced fibrosis, had less co-
morbidities and co-medications. These factors theoretically support
better response to treatment, but it was not confirmed with the final
efficacy analysis. It was clearly demonstrated that adding RBV to the 12
weeks regimen did not improve efficacy and even caused insignificant
reduction of SVR rate and the only factor associated with SVR reduction
in multivariate analysis was the 8 week therapy.
It was documented previously [11], that measurement of the viral
Table 1
Baseline characteristics of patients treated with OBV/PTV/r + DSV for 8 weeks
or 12 weeks (eligible for 8 weeks).


























BMI mean ± SD; min-max 25 ± 4; 17-
43
25 ± 4; 16-
50
0.13
Comorbidities, n(%) 60 (30%) 322 (56%) < 0.001
Any comorbidity 18 (9%) 146 (25%) < 0.001
Hypertension 5 (2.5%) 35 (6.1%) 0.06
Diabetes 2 (1%) 26 (4.5%) 0.03
Renal disease 2 (1%) 12 (2.1%) 0.52
Autoimmune diseases 2 (1%) 8 (1.4%) 1.00
Non-HCC tumors other 47 (24%) 239 (41.6%) < 0.001
Concomitant medications, n(%) 56 (28%) 259 (45%) < 0.001
Liver fibrosis, n(%)
F0 4 (2%) 0
F1 161 (82%) 351 (61%) < 0.001
F2 32 (16%) 223 (39%)
OLTx experienced, n(%) 0 0 N/A
HCC history, n(%) 0 4 (0.7%) N/A
Liver fibrosis assessment, n(%)
biopsy 16 (8%) 186 (32.4%)
TE 130 (66%) 309 (53.8%)
SWE 51 (26%) 78 (13.6%) < 0.001
ARFI 0 1 (0.2%)
HIV coinfection 1 (0.5%) 9 (1.6%) 0.46
HBV coinfection
HBsAg(+) 0 4 (0.7%) N/A
HBsAg(−)/anti-HBctotal(+) 16 (8%) 62 (10.8%) 0.34
ALT IU/L, mean ± SD 61 ± 57 64 ± 50 0.17
Bilirubin mg/dL, mean ± SD 0.67 ± 0.36 0.69 ± 0.4 0.54
Albumin g/dL, mean ± SD 4.2 ± 0.5 4.1 ± 0.4 0.02
Albumin <3 g/dl, n (%) 1 (0.5%) 2 (0.3%) 1.00
Creatinine mg/dL, mean ± SD 0.83 ± 0.49 0.96 ± 1.1 0.30
Hemoglobin g/dL, mean ± SD 14.0 ± 1.9 14.4 ± 1.9 0.01
Platelets, x1000/μL, mean ± SD 228 ± 65 220 ± 64 0.12
Platelets < 100 000/μL, n (%) 2 (1%) 9 (1.6%) 0.73
HCV RNA x106 IU/ml, mean ± SD 1.9 ± 3.1 1.98 ± 6.5 0.42
HCV RNA >6x10∧6 IU/ml, n (%) 16 (8%) 31 (5.4%) 0.17
Abbreviations: OBV - ombitasvir; PTV - paritaprevir; r - ritonavir; DSV - dasa-
buvir; BMI - body mass index; SD - standard deviation; HCC - hepatocellular
carcinoma; HCV - hepatitis C virus; F - fibrosis; OLTx - orthotopic liver trans-
plantation; TE - transient elastography; SWE - shear wave elastography; ARFI -
acoustic radiation force impulse; HIV - human immunodeficiency virus; HBV -
hepatitis B virus; HBsAg - hepatitis B surface antigen; anti-HBc - antibody to the
hepatitis B core antigen; ALT - alanine aminotransferase; HCV RNA - hepatitis C
virus ribonucleic acid.
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load at the end of direct-acting antiviral (DAA) treatment does not
predict the final response. Patients with detectable but not quantifiable
HCV RNA at the EOT, can finally either achieve or not achieve SVR.
Therefore the majority of the RWE studies even do not provide the EOT
viral load information. Since the protocol of the national therapeutic
program includes HCV RNA examination at the EOT we are able to
provide this unique information. As it was demonstrated in Tables 2
and 3, non-responders after both 8 and 12 weeks regimens had either
detectable or non-detectable HCV RNA at the EOT.
There were 4 patients with hepatocellular carcinoma (HCC) but
without cirrhosis, which was uncommon but possible if cirrhosis was
diagnosed using liver biopsy. Our patients were diagnosed for the dis-
ease advancement using liver elastography, which is affected by several
factors additional to fibrosis, such as inflammation, steatosis or blood
circulation. Therefore non-cirrhotics with HCC are more likely to be
found with elastography which is currently an approved technique for
the liver advancement evaluation.
It should be noted that almost all patients (8/9) who experienced
treatment failure in the 8-week arm were males. According to the recent
studies males are less likely to be non-adherent, but on the other hand
heavy drinkers, who are usually male more often discontinue therapy,
Fig. 1. Treatment effectiveness (SVR rate)
of OPrD with and without RBV adminis-
tered for 8 or 12 weeks, calculated ac-
cording to ITT and mITT analysis; only
statistically significant differences were in-
dicated.
Abbreviations: SVR - sustained virological
response; OBV - ombitasvir; PTV - par-
itaprevir; r - ritonavir; DSV - dasabuvir; RBV
- ribavirin; ITT - intent-to-treat; mITT -
modified intent-to-treat.
Table 2
Characteristics of 9 non-responders to 8 weeks regimens.




reason, chance of SVR if
extended)
Female 1 OPrD 1 0.07 TD none
Male 1 OPrD 1 1.02 TND none
Male 2 OPrD 2 1.81 TD none
Male 3 OPrD 1 4.63 TND none
Male 4 OPrD 1 5.98 TND none
Male 5 OPrD 1 1.30 TD Treatment stopped for 1
week (4–5wk) because of
alcohol abuse
Male 6 OPrD 1 2.90 TD none
Male 7 OPrD 1 4.50 TND none
Male 8 OPrD 1 5.60 TD none
Abbreviations: HCV RNA - hepatitis C virus ribonucleic acid; EOT - end of
treatment; SVR - sustained virologic response; OPrD - ombitasvir, paritaprevir,
ritonavir and dasabuvir; TD - target detected; TND - target not detected; pegIFN
- pegylated interferon; RBV – ribavirin.
Table 3
Characteristics of 7 non-responders to 12 weeks regimens.






Female 1 OPrD 1 0.51 TND none
Female 2 OPrD 2 7.46 TND none
Female 3 OPrD 2 2.68 TD none
Female 4 OPrD + RBV 2 0.52 TND none
Male 1 OPrD 1 4.75 TND none
Male 2 OPrD 2 3.38 TND none
Male 3 OPrD + RBV 2 3.21 TND none
Abbreviations: HCV RNA - hepatitis C virus ribonucleic acid; EOT - end of
treatment; SVR - sustained virologic response; OPrD - ombitasvir, paritaprevir,
ritonavir and dasabuvir; TD - target detected; TND - target not detected; RBV –
ribavirin.
Table 4






12 weeks + RBV
n = 53
Treatment course, n(%)
Therapy discontinuation 3 (1.5%) 4 (0.8%) 1 (1.9%)
Therapy modification 0 0 5 (9.4%)
Patients with at least one AE 25 (13%) 97 (19%) 21 (40%)
Serious adverse events 0 4 (0.8%)a 1 (1.9%)b
Most common AEs (> 2%)
Weakness/fatigue 8 (4%) 40 (8%) 11 (21%)
Sleep disorder 4 (2%) 10 (2%) 3 (5.7%)
Headache 9 (5%) 6 (1%) 3 (5.7%)
Pruritus 5 (3%) 14 (3%) 0
Laboratory abnormalities
Elevated ALT, >ULN 0 1 (0.2%) 0
Bilirubin, > 1.5 ULN 1 (0.5%) 2 (0.4%) 2 (3.8%)
Hemoglobin, < 9.5 g/dl 0 2 (0.4%) 0
eGFR, < 60 ml/min/1.73m2 0 1 (0.2%) 0
Death in treatment course 0 0 0
Abbreviations: RBV - ribavirin; AE - adverse event; ULN - upper limit of norm;
eGFR - estimated glomerular filtration rate.
a Allergic reaction, headache, ALT elevation (hospitalization), weakness.
b Weakness.
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that can result in lower response rate [18,20,21]. From our data, we
were not able to find a clear reason of non-response, particularly in
patients treated for 8 weeks. Unfortunately, EpiTer-2 database does not
include detailed, day-by-day adherence data, but it provides informa-
tion on discontinuation or modification of treatment. Based on this
information we found that between 2 males with clarified possible
reasons of no response only 1 stopped the treatment for one week,
whereas the other patient was non-responder to previous interferon
based therapy, which as a matter of fact should not affect response to
interferon-free treatment. It is worth to mention that 5 of 9 non-re-
sponders from the 8-weeks regimen arm had detectable viral load at the
EOT compared to only 1 of 7 in the 12-weeks regimen arm. The most
probable reason of non-response in these patients was non-adherence,
but we were not able to establish why it was more frequent among
patients treated for 8 weeks.
5. Conclusions
Concluding, we confirmed high effectiveness of both 8 and 12-
weeks OPrD regimens in GT1b HCV infected patients with non-ad-
vanced fibrosis. Despite of reduced SVR rate after 8 weeks regimen,
there is no need to extend the therapy to 12-weeks in vast majority of
such patients and no need to add RBV. However the decision on
shortening the treatment to 8 weeks should take into account the risk of
lower response rate demonstrated in males.
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